Literature DB >> 29936437

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors.

Anissa Roger1, Matthieu Groh2, Gwenael Lorillon3, Claire Le Pendu2, Jeremy Maillet4, Dimitri Arangalage5,6,7, Abdellatif Tazi3,6,8, Celeste Lebbe1,6,9, Barouyr Baroudjian1, Julie Delyon1,6,9.   

Abstract

Entities:  

Keywords:  arthritis; granulomatosis with polyangiitis; systemic vasculitis

Mesh：

Year:  2018        PMID： 29936437     DOI： 10.1136/annrheumdis-2018-213857

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

1.  Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis.

Authors:  Jagdeep Singh; Ranjana Walker Minz; Biman Saikia; Ritambhra Nada; Aman Sharma; Saket Jha; Shashi Anand; Manish Rathi; Sanjay D'Cruz
Journal:  Clin Exp Med       Date:  2022-10-11       Impact factor: 5.057

Review 2.  Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Konstantinos Melissaropoulos; Kalliopi Klavdianou; Alexandra Filippopoulou; Fotini Kalofonou; Haralabos Kalofonos; Dimitrios Daoussis
Journal:  Int J Mol Sci       Date:  2020-05-11       Impact factor: 5.923

3.  Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database.

Authors:  Quentin Scanvion; Johana Béné; Sophie Gautier; Aurélie Grandvuillemin; Christine Le Beller; Chouki Chenaf; Nicolas Etienne; Solenn Brousseau; Alexis B Cortot; Laurent Mortier; Delphine Staumont-Sallé; Franck Morschhauser; Alexandra Forestier; Matthieu Groh; David Launay; Eric Hachulla; Myriam Labalette; Jean-Emmanuel Kahn; Guillaume Lefèvre
Journal:  Oncoimmunology       Date:  2020-04-07       Impact factor: 8.110

4.  Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.

Authors:  Marie Kostine; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

5.  Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.

Authors:  Noha Abdel-Wahab; Maria E Suarez-Almazor
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

6.  Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.

Authors:  Jan Leipe; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

7.  Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report.

Authors:  Masanori Harada; Hyogo Naoi; Kazuyo Yasuda; Yutaro Ito; Namio Kagoo; Tsutomu Kubota; Koshiro Ichijo; Eisuke Mochizuki; Masahiro Uehara; Shun Matsuura; Masaru Tsukui; Naoki Koshimizu
Journal:  BMC Pulm Med       Date:  2021-01-06       Impact factor: 3.317

8.  Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis.

Authors:  Chie Miyabe; Yupeng Dong; Takaharu Ikeda; Kazuo Takahashi; Yoshishige Miyabe; Tamihiro Kawakami
Journal:  Sci Rep       Date:  2021-10-08       Impact factor: 4.379

9.  Eosinophilic Vasculitis and Arteritic Anterior Ischemic Optic Neuropathy Associated With Anti-PD-L1 Therapy.

Authors:  Ella C Berry; Sean Mullany; Alannah Quinlivan; Amelia Craig; Julia New-Tolley; James Slattery; Shawgi Sukumaran; Sonja Klebe; Jamie E Craig; Owen M Siggs; Mihir D Wechalekar
Journal:  J Immunother       Date:  2022-01-01       Impact factor: 4.456
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.